Literature DB >> 8842508

Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia.

A Fujiki1, M Tani, S Yoshida, H Inoue.   

Abstract

We evaluated the electrophysiological mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline in seven patients, pilsicainide in two, and disopyramide in two, and procainamide in three) in the induction of orthodromic atrioventricular re-entrant tachycardia (AVRT). In 14 patients (10 males, 4 females; mean age 37 +/- 18 years) who had inducible AVRT despite the administration of class I drugs, electrophysiological effects of class I antiarrhythmic drugs were evaluated using programmed electrical stimulation techniques. In 4 out of 6 patients with a manifest accessory pathway, class I drugs induced unidirectional conduction block of the accessory pathway (antegrade conduction block associated with preserved retrograde conduction) and enhanced the induction of AVRT with atrial extrastimulation. In eight patients with a concealed accessory pathway, the outward or inward expansion of the tachycardia induction zone was observed in patients who had greater prolongation of the conduction time than the refractory period of the retrograde accessory pathway after class I drugs. During ventricular extrastimulation, the induction of bundle branch re-entry after class I drugs initiated the AVRT in patients with either manifest or concealed accessory pathways. We conclude that the adverse effects of class I drugs are mainly due to induction of unidirectional retrograde conduction of the manifest accessory pathway and the greater prolongation of the retrograde conduction time of the concealed accessory pathway than the refractory period, regardless of the sub-classification of class I drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842508     DOI: 10.1007/bf00823594

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  11 in total

1.  Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.

Authors:  M Eldar; M A Ruder; J C Davis; J A Abbott; J Seger; J C Griffin; M M Scheinman
Journal:  Pacing Clin Electrophysiol       Date:  1986-09       Impact factor: 1.976

2.  Radiofrequency current catheter ablation of accessory atrioventricular pathways.

Authors:  K H Kuck; M Schlüter; M Geiger; J Siebels; W Duckeck
Journal:  Lancet       Date:  1991-06-29       Impact factor: 79.321

3.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

4.  Electrophysiologic mechanisms of orthodromic tachycardia initiation during ventricular pacing in the Wolff-Parkinson-White syndrome.

Authors:  M Akhtar; M H Lehmann; S T Denker; R Mahmud; P Tchou; M Jazayeri
Journal:  J Am Coll Cardiol       Date:  1987-01       Impact factor: 24.094

5.  Ventricular fibrillation in the Wolff-Parkinson-White syndrome.

Authors:  G J Klein; T M Bashore; T D Sellers; E L Pritchett; W M Smith; J J Gallagher
Journal:  N Engl J Med       Date:  1979-11-15       Impact factor: 91.245

6.  Electrophysiologic effects and efficacy of cibenzoline in patients with supraventricular tachycardia.

Authors:  A Fujiki; K Mizumaki; M Tani; S Yoshida; S Sasayama
Journal:  J Cardiovasc Pharmacol       Date:  1992-09       Impact factor: 3.105

7.  Procainamide in the induction and perpetuation of ventricular tachycardia in man.

Authors:  P S Kang; J A Gomes; N El-Sherif
Journal:  Pacing Clin Electrophysiol       Date:  1982-05       Impact factor: 1.976

8.  Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.

Authors:  J L Cockrell; M M Scheinman; C Titus; I Helmy; J J Langberg; M A Lee; J C Griffin
Journal:  Ann Intern Med       Date:  1991-02-01       Impact factor: 25.391

9.  Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.

Authors:  C R Kerr; E N Prystowsky; W M Smith; L Cook; J J Gallagher
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

10.  Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia.

Authors:  P K Au; A K Bhandari; R Bream; D Schreck; R Siddiqi; S H Rahimtoola
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

View more
  1 in total

1.  Ventricular anti-arrhythmic effects of heptanol in hypokalaemic, Langendorff-perfused mouse hearts.

Authors:  Gary Tse; Vivian Tse; Jie Ming Yeo
Journal:  Biomed Rep       Date:  2016-01-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.